CYDY
CytoDyn Inc. [CYDY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CYDY Stock Summary
Top 10 Correlated ETFs
CYDY
Top 10 Correlated Stocks
CYDY
In the News
CYDY Financial details
Company Rating
-
Market Cap
154.81M
Income
-55.65M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-2.61
Forward P/E
-
PEG
0.3
P/S
-
P/B
-1.63
P/C
-
P/FCF
-10.38
Quick Ratio
0.02
Current Ratio
0.09
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-77.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20%
-
-
-
-
SMA20
-8.7%
SMA50
-
SMA100
75%
Inst Own
-
Inst Trans
-
ROA
-590%
ROE
65%
ROC
0.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.15-0.42
52W High
-
52W Low
-
RSI
51.97
Rel Volume
0.32
Avg Volume
2.98M
Volume
968.77K
Perf Week
1.41%
Perf Month
-11.2%
Perf Quarter
70.37%
Perf Half Y
62.31%
-
-
-
-
Beta
0.188
-
-
Volatility
0.01%, 0.02%
Prev Close
12.75%
Price
0.23
Change
15%
Company Profile
- Volume Average 2.98M
- Market Capitalization 154.81M
- Employee 12
- CEO Dr. Jacob P. Lalezari M.D.
- Headquarters Vancouver,WA,US
- IPO Date 2006-12-13
-
Website
https://www.cytodyn.com 
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
